001     154641
005     20240612120602.0
024 7 _ |a 10.1186/s13073-020-00823-5
|2 doi
024 7 _ |a pmid:33441124
|2 pmid
024 7 _ |a pmc:PMC7805430
|2 pmc
024 7 _ |a altmetric:97621757
|2 altmetric
037 _ _ |a DZNE-2021-00289
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Aschenbrenner, Anna C
|0 P:(DE-2719)2812913
|b 0
|e First author
245 _ _ |a Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients.
260 _ _ |a London
|c 2021
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1718105474_5894
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The SARS-CoV-2 pandemic is currently leading to increasing numbers of COVID-19 patients all over the world. Clinical presentations range from asymptomatic, mild respiratory tract infection, to severe cases with acute respiratory distress syndrome, respiratory failure, and death. Reports on a dysregulated immune system in the severe cases call for a better characterization and understanding of the changes in the immune system.In order to dissect COVID-19-driven immune host responses, we performed RNA-seq of whole blood cell transcriptomes and granulocyte preparations from mild and severe COVID-19 patients and analyzed the data using a combination of conventional and data-driven co-expression analysis. Additionally, publicly available data was used to show the distinction from COVID-19 to other diseases. Reverse drug target prediction was used to identify known or novel drug candidates based on finding from data-driven findings.Here, we profiled whole blood transcriptomes of 39 COVID-19 patients and 10 control donors enabling a data-driven stratification based on molecular phenotype. Neutrophil activation-associated signatures were prominently enriched in severe patient groups, which was corroborated in whole blood transcriptomes from an independent second cohort of 30 as well as in granulocyte samples from a third cohort of 16 COVID-19 patients (44 samples). Comparison of COVID-19 blood transcriptomes with those of a collection of over 3100 samples derived from 12 different viral infections, inflammatory diseases, and independent control samples revealed highly specific transcriptome signatures for COVID-19. Further, stratified transcriptomes predicted patient subgroup-specific drug candidates targeting the dysregulated systemic immune response of the host.Our study provides novel insights in the distinct molecular subgroups or phenotypes that are not simply explained by clinical parameters. We show that whole blood transcriptomes are extremely informative for COVID-19 since they capture granulocytes which are major drivers of disease severity.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Blood transcriptomics
|2 Other
650 _ 7 |a COVID-19
|2 Other
650 _ 7 |a Co-expression analysis
|2 Other
650 _ 7 |a Drug repurposing
|2 Other
650 _ 7 |a Granulocytes
|2 Other
650 _ 7 |a Molecular disease phenotypes
|2 Other
650 _ 7 |a Neutrophils
|2 Other
650 _ 7 |a Stratification
|2 Other
650 _ 7 |a Transcriptome
|2 Other
650 _ 7 |a Antiviral Agents
|2 NLM Chemicals
650 _ 7 |a RNA
|0 63231-63-0
|2 NLM Chemicals
650 _ 2 |a Antiviral Agents: therapeutic use
|2 MeSH
650 _ 2 |a COVID-19: drug therapy
|2 MeSH
650 _ 2 |a COVID-19: pathology
|2 MeSH
650 _ 2 |a COVID-19: virology
|2 MeSH
650 _ 2 |a Case-Control Studies
|2 MeSH
650 _ 2 |a Down-Regulation
|2 MeSH
650 _ 2 |a Drug Repositioning
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neutrophils: cytology
|2 MeSH
650 _ 2 |a Neutrophils: immunology
|2 MeSH
650 _ 2 |a Neutrophils: metabolism
|2 MeSH
650 _ 2 |a Phenotype
|2 MeSH
650 _ 2 |a Principal Component Analysis
|2 MeSH
650 _ 2 |a RNA: blood
|2 MeSH
650 _ 2 |a RNA: chemistry
|2 MeSH
650 _ 2 |a RNA: metabolism
|2 MeSH
650 _ 2 |a Sequence Analysis, RNA
|2 MeSH
650 _ 2 |a Severity of Illness Index
|2 MeSH
650 _ 2 |a Transcriptome
|2 MeSH
650 _ 2 |a Up-Regulation
|2 MeSH
693 _ _ |0 EXP:(DE-2719)PRECISE-20190321
|5 EXP:(DE-2719)PRECISE-20190321
|e Platform for Single Cell Genomics and Epigenomics at DZNE University of Bonn
|x 0
693 _ _ |0 EXP:(DE-2719)Rhineland Study-20190321
|5 EXP:(DE-2719)Rhineland Study-20190321
|e Rhineland Study / Bonn
|x 1
700 1 _ |a Mouktaroudi, Maria
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Krämer, Benjamin
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Oestreich, Marie
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Antonakos, Nikolaos
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Nuesch-Germano, Melanie
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Gkizeli, Konstantina
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Bonaguro, Lorenzo
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Reusch, Nico
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Baßler, Kevin
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Saridaki, Maria
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Knoll, Rainer
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Pecht, Tal
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Kapellos, Theodore S
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Doulou, Sarandia
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Kröger, Charlotte
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Herbert, Miriam
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Holsten, Lisa
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Horne, Arik
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Gemünd, Ioanna D
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Rovina, Nikoletta
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Agrawal, Shobhit
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Dahm, Kilian
|0 P:(DE-HGF)0
|b 22
700 1 _ |a van Uelft, Martina
|0 P:(DE-HGF)0
|b 23
700 1 _ |a Drews, Anna
|0 P:(DE-2719)2812302
|b 24
700 1 _ |a Lenkeit, Lena
|0 P:(DE-HGF)0
|b 25
700 1 _ |a Bruse, Niklas
|0 P:(DE-HGF)0
|b 26
700 1 _ |a Gerretsen, Jelle
|0 P:(DE-HGF)0
|b 27
700 1 _ |a Gierlich, Jannik
|0 P:(DE-HGF)0
|b 28
700 1 _ |a Becker, Matthias
|0 P:(DE-2719)2812750
|b 29
700 1 _ |a Händler, Kristian
|0 P:(DE-2719)2812735
|b 30
700 1 _ |a Kraut, Michael
|0 P:(DE-2719)9000840
|b 31
700 1 _ |a Theis, Heidi
|0 P:(DE-2719)2812165
|b 32
700 1 _ |a Mengiste, Simachew
|0 P:(DE-HGF)0
|b 33
700 1 _ |a De Domenico, Elena
|0 P:(DE-2719)9000846
|b 34
700 1 _ |a Schulte-Schrepping, Jonas
|0 P:(DE-HGF)0
|b 35
700 1 _ |a Seep, Lea
|0 P:(DE-HGF)0
|b 36
700 1 _ |a Raabe, Jan
|0 P:(DE-HGF)0
|b 37
700 1 _ |a Hoffmeister, Christoph
|0 P:(DE-HGF)0
|b 38
700 1 _ |a ToVinh, Michael
|0 P:(DE-HGF)0
|b 39
700 1 _ |a Keitel, Verena
|0 P:(DE-HGF)0
|b 40
700 1 _ |a Rieke, Gereon
|0 P:(DE-HGF)0
|b 41
700 1 _ |a Talevi, Valentina
|0 P:(DE-2719)9001002
|b 42
700 1 _ |a Skowasch, Dirk
|0 P:(DE-HGF)0
|b 43
700 1 _ |a Aziz, N. Ahmad
|0 P:(DE-2719)2812578
|b 44
|u dzne
700 1 _ |a Pickkers, Peter
|0 P:(DE-HGF)0
|b 45
700 1 _ |a van de Veerdonk, Frank L
|0 P:(DE-HGF)0
|b 46
700 1 _ |a Netea, Mihai G
|0 P:(DE-HGF)0
|b 47
700 1 _ |a Schultze, Joachim L
|0 P:(DE-2719)2811660
|b 48
700 1 _ |a Kox, Matthijs
|0 P:(DE-HGF)0
|b 49
700 1 _ |a Breteler, Monique M B
|0 P:(DE-2719)2810403
|b 50
700 1 _ |a Nattermann, Jacob
|0 P:(DE-HGF)0
|b 51
700 1 _ |a Koutsoukou, Antonia
|0 P:(DE-HGF)0
|b 52
700 1 _ |a Giamarellos-Bourboulis, Evangelos J
|0 P:(DE-HGF)0
|b 53
700 1 _ |a Ulas, Thomas
|0 P:(DE-2719)9000845
|b 54
|e Last author
700 1 _ |a Initiative, German COVID-19 Omics
|0 P:(DE-HGF)0
|b 55
|e Collaboration Author
700 1 _ |a Altmüller, Janine
|0 P:(DE-HGF)0
|b 56
700 1 _ |a Angelov, Angel
|0 P:(DE-HGF)0
|b 57
700 1 _ |a Bals, Robert
|0 P:(DE-HGF)0
|b 58
700 1 _ |a Bartholomäus, Alexander
|0 P:(DE-HGF)0
|b 59
700 1 _ |a Becker, Anke
|0 P:(DE-HGF)0
|b 60
700 1 _ |a Bitzer, Michael
|0 P:(DE-HGF)0
|b 61
700 1 _ |a Bonifacio, Ezio
|0 P:(DE-HGF)0
|b 62
700 1 _ |a Bork, Peer
|0 P:(DE-HGF)0
|b 63
700 1 _ |a Casadei, Nicolas
|0 P:(DE-HGF)0
|b 64
700 1 _ |a Clavel, Thomas
|0 P:(DE-HGF)0
|b 65
700 1 _ |a Colome-Tatche, Maria
|0 P:(DE-HGF)0
|b 66
700 1 _ |a Diefenbach, Andreas
|0 P:(DE-HGF)0
|b 67
700 1 _ |a Dilthey, Alexander
|0 P:(DE-HGF)0
|b 68
700 1 _ |a Fischer, Nicole
|0 P:(DE-HGF)0
|b 69
700 1 _ |a Förstner, Konrad
|0 P:(DE-HGF)0
|b 70
700 1 _ |a Franzenburg, Sören
|0 P:(DE-HGF)0
|b 71
700 1 _ |a Frick, Julia-Stefanie
|0 P:(DE-HGF)0
|b 72
700 1 _ |a Gabernet, Gisela
|0 P:(DE-HGF)0
|b 73
700 1 _ |a Gagneur, Julien
|0 P:(DE-HGF)0
|b 74
700 1 _ |a Ganzenmüller, Tina
|0 P:(DE-HGF)0
|b 75
700 1 _ |a Göpel, Siri
|0 P:(DE-HGF)0
|b 76
700 1 _ |a Goesmann, Alexander
|0 P:(DE-HGF)0
|b 77
700 1 _ |a Hain, Torsten
|0 P:(DE-HGF)0
|b 78
700 1 _ |a Heimbach, André
|0 P:(DE-HGF)0
|b 79
700 1 _ |a Hummel, Michael
|0 P:(DE-HGF)0
|b 80
700 1 _ |a Iftner, Angelika
|0 P:(DE-HGF)0
|b 81
700 1 _ |a Iftner, Thomas
|0 P:(DE-HGF)0
|b 82
700 1 _ |a Janssen, Stefan
|0 P:(DE-HGF)0
|b 83
700 1 _ |a Kalinowski, Jörn
|0 P:(DE-HGF)0
|b 84
700 1 _ |a Kallies, René
|0 P:(DE-HGF)0
|b 85
700 1 _ |a Kehr, Birte
|0 P:(DE-HGF)0
|b 86
700 1 _ |a Keller, Andreas
|0 P:(DE-HGF)0
|b 87
700 1 _ |a Kim-Hellmuth, Sarah
|0 P:(DE-HGF)0
|b 88
700 1 _ |a Klein, Christoph
|0 P:(DE-HGF)0
|b 89
700 1 _ |a Kohlbacher, Oliver
|0 P:(DE-HGF)0
|b 90
700 1 _ |a Köhrer, Karl
|0 P:(DE-HGF)0
|b 91
700 1 _ |a Korbel, Jan
|0 P:(DE-HGF)0
|b 92
700 1 _ |a Kühnert, Denise
|0 P:(DE-HGF)0
|b 93
700 1 _ |a Kurth, Ingo
|0 P:(DE-HGF)0
|b 94
700 1 _ |a Landthaler, Markus
|0 P:(DE-HGF)0
|b 95
700 1 _ |a Li, Yang
|0 P:(DE-HGF)0
|b 96
700 1 _ |a Ludwig, Kerstin
|0 P:(DE-HGF)0
|b 97
700 1 _ |a Makarewicz, Oliwia
|0 P:(DE-HGF)0
|b 98
700 1 _ |a Marz, Manja
|0 P:(DE-HGF)0
|b 99
700 1 _ |a McHardy, Alice
|0 P:(DE-HGF)0
|b 100
700 1 _ |a Mertes, Christian
|0 P:(DE-HGF)0
|b 101
700 1 _ |a Nöthen, Markus
|0 P:(DE-HGF)0
|b 102
700 1 _ |a Nürnberg, Peter
|0 P:(DE-HGF)0
|b 103
700 1 _ |a Ohler, Uwe
|0 P:(DE-HGF)0
|b 104
700 1 _ |a Ossowski, Stephan
|0 P:(DE-HGF)0
|b 105
700 1 _ |a Overmann, Jörg
|0 P:(DE-HGF)0
|b 106
700 1 _ |a Pfeffer, Klaus
|0 P:(DE-HGF)0
|b 107
700 1 _ |a Poetsch, Anna R
|0 P:(DE-HGF)0
|b 108
700 1 _ |a Pühler, Alfred
|0 P:(DE-HGF)0
|b 109
700 1 _ |a Rajewsky, Nikolaus
|0 P:(DE-HGF)0
|b 110
700 1 _ |a Ralser, Markus
|0 P:(DE-HGF)0
|b 111
700 1 _ |a Rieß, Olaf
|0 P:(DE-HGF)0
|b 112
700 1 _ |a Ripke, Stephan
|0 P:(DE-HGF)0
|b 113
700 1 _ |a Nunes da Rocha, Ulisses
|0 P:(DE-HGF)0
|b 114
700 1 _ |a Rosenstiel, Philip
|0 P:(DE-HGF)0
|b 115
700 1 _ |a Saliba, Antoine-Emmanuel
|0 P:(DE-HGF)0
|b 116
700 1 _ |a Sander, Leif Erik
|0 P:(DE-HGF)0
|b 117
700 1 _ |a Sawitzki, Birgit
|0 P:(DE-HGF)0
|b 118
700 1 _ |a Schiffer, Philipp
|0 P:(DE-HGF)0
|b 119
700 1 _ |a Schneider, Wulf
|0 P:(DE-HGF)0
|b 120
700 1 _ |a Schulte, Eva-Christina
|0 P:(DE-HGF)0
|b 121
700 1 _ |a Schultze, Joachim L
|0 P:(DE-2719)2811660
|b 122
700 1 _ |a Sczyrba, Alexander
|0 P:(DE-HGF)0
|b 123
700 1 _ |a Singh, Yogesh
|0 P:(DE-HGF)0
|b 124
700 1 _ |a Sonnabend, Michael
|0 P:(DE-HGF)0
|b 125
700 1 _ |a Stegle, Oliver
|0 P:(DE-HGF)0
|b 126
700 1 _ |a Stoye, Jens
|0 P:(DE-HGF)0
|b 127
700 1 _ |a Theis, Fabian
|0 P:(DE-HGF)0
|b 128
700 1 _ |a Vehreschild, Janne
|0 P:(DE-HGF)0
|b 129
700 1 _ |a Vogel, Jörg
|0 P:(DE-HGF)0
|b 130
700 1 _ |a von Kleist, Max
|0 P:(DE-HGF)0
|b 131
700 1 _ |a Walker, Andreas
|0 P:(DE-HGF)0
|b 132
700 1 _ |a Walter, Jörn
|0 P:(DE-HGF)0
|b 133
700 1 _ |a Wieczorek, Dagmar
|0 P:(DE-HGF)0
|b 134
700 1 _ |a Winkler, Sylke
|0 P:(DE-HGF)0
|b 135
700 1 _ |a Ziebuhr, John
|0 P:(DE-HGF)0
|b 136
773 _ _ |a 10.1186/s13073-020-00823-5
|g Vol. 13, no. 1, p. 7
|0 PERI:(DE-600)2484394-5
|n 1
|p 7
|t Genome medicine
|v 13
|y 2021
|x 1756-994X
856 4 _ |u https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-020-00823-5
856 4 _ |u https://pub.dzne.de/record/154641/files/7803.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/154641/files/7803.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:154641
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2812913
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2812302
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2812750
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2812735
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)9000840
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 32
|6 P:(DE-2719)2812165
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 34
|6 P:(DE-2719)9000846
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 42
|6 P:(DE-2719)9001002
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 44
|6 P:(DE-2719)2812578
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 48
|6 P:(DE-2719)2811660
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 50
|6 P:(DE-2719)2810403
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 54
|6 P:(DE-2719)9000845
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 122
|6 P:(DE-2719)2811660
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 1
913 0 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-341
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Molecular Signaling
|x 0
914 1 _ |y 2021
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-03
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-03
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GENOME MED : 2021
|d 2022-11-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-14T16:20:36Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-14T16:20:36Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-02-14T16:20:36Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-22
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b GENOME MED : 2021
|d 2022-11-22
920 1 _ |0 I:(DE-2719)1013031
|k Schultze - PRECISE
|l Platform for Single Cell Genomics and Epigenomics
|x 0
920 1 _ |0 I:(DE-2719)1013038
|k AG Schultze
|l Clinical Single Cell Omics (CSCO) / Systems Medicine
|x 1
920 1 _ |0 I:(DE-2719)1012001
|k AG Breteler
|l Population Health Sciences
|x 2
920 1 _ |0 I:(DE-2719)5000071
|k AG Aziz
|l Population & Clinical Neuroepidemiology
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1013031
980 _ _ |a I:(DE-2719)1013038
980 _ _ |a I:(DE-2719)1012001
980 _ _ |a I:(DE-2719)5000071
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21